WallStSmart
QNRX

Quoin Pharmaceuticals Ltd DRC

NASDAQ: QNRX · HEALTHCARE · BIOTECHNOLOGY

$6.07
+4.66% today

Updated 2026-06-05

Market cap
$9.34M
P/E ratio
P/S ratio
EPS (TTM)
$-10.07
Dividend yield
52W range
$4 – $24
Volume
0.0M

Quoin Pharmaceuticals Ltd DRC (QNRX) Financial statements

SEC filings — annual and quarterly data.

Profit margin
0.00%
Operating margin
0.00%
ROE
-193.51%
ROA
-76.20%
Debt/equity

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2015$-2.62M
2016$-280000.00$15.32M100.00%-5,470.36%-5,470.36%
2017$10.17M
2018$-280000.00$15.32M100.00%-5,470.36%-5,470.36%
2019$0.00$-1.56M
2020$0.00$-2.10M
2021$0.00$-21.46M
2022$0.00$-9.38M
2023$0.00$-8.69M
2024$0.00$-8.96M
2025$0.00$-15.80M

Frequently asked questions

How much free cash flow does QNRX generate?

QNRX produced $-13.54M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is QNRX's balance sheet healthy?

QNRX holds $3.82B in cash and equivalents against — in long-term debt, on $13.12M of shareholder equity. That debt is best read against the cash flow the business throws off each year.